Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Recurrent or Metastatic Triple-negative Breast Cancer: a Double-blinded Randomized Controlled Clinical Trial

NCT03932526 is registered in ClinicalTrials.gov with Liaoning Cancer Hospital & Institute as lead sponsor.

NCT NCT03932526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03932526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Recurrent or Metastatic Triple-negative Breast Cancer: a Double-blinded Randomized Controlled Clinical Trial
Lead sponsor
Liaoning Cancer Hospital & Institute
Phase
Phase 2
Overall status
Unknown status
Start date
June 24, 2019
Completion date
June 26, 2023
Enrollment
184 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer